Meditus (Acetylcysteine)

Acetylcysteine breaks disulfide bonds within mucus glycoproteins, reducing the viscosity of the secretions. This chemical action makes the mucus less sticky and easier to expectorate. Additionally, it replenishes intracellular glutathione, supporting antioxidant defenses in the respiratory tract.

The specific dose of Meditus is determined by the prescribing healthcare professional based on the patient’s condition, age, weight and renal function. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for acetylcysteine in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Meditus, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Acetylcysteine is a thiol‑containing mucolytic that directly cleaves disulfide bonds, whereas other agents such as carbocysteine or ambroxol act mainly by stimulating ciliary activity or altering mucus composition. Acetylcysteine also offers antioxidant benefits, making it a distinct option for patients needing both mucus thinning and oxidative protection.

Meditus should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain its stability and effectiveness.

Meditus is taken orally as directed by the prescriber. It may be swallowed whole with water or, if a liquid formulation is supplied, measured with a calibrated device and ingested. Patients should not crush or chew tablets unless specifically instructed.

Serious adverse reactions, although rare, include anaphylaxis, severe skin reactions such as Stevens‑Johnson syndrome, bronchospasm, hepatic dysfunction and angioedema. Any signs of these conditions require immediate medical attention.

Meditus should be avoided in individuals with known hypersensitivity to acetylcysteine or any excipients in the formulation. Patients with severe renal impairment, uncontrolled asthma or a history of severe allergic reactions should discuss use with their healthcare provider before starting therapy.